Publications by authors named "M Wiseman"
Background: Alopecia areata (AA) is a T-cell-mediated autoimmune disease that significantly impacts patient quality of life. The breakdown of hair follicle immune privilege underlies AA pathogenesis. However, the precise mechanism of this breakdown remains unclear.
View Article and Find Full Text PDFPruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
View Article and Find Full Text PDFIntroduction: A retrospective review of patients treated for retinoblastoma who developed a non-pineoblastoma second primary malignant neoplasm (SPMN) was performed.
Methods: The demographics, clinical features and treatments for retinoblastoma, pathologic types of non-pineoblastoma second primary malignant neoplasm (SPMN), intervals between the retinoblastoma diagnosis and treatment and diagnosis of non-pineoblastoma SPMN, treatment provided for the SPMN, and the survival outcomes of the patients were evaluated.
Results: Of 550 patients treated initially for retinoblastoma, this series used the 15 (2.
Article Synopsis
- Alopecia areata (AA) is a hair loss disorder that significantly affects quality of life, and studies have shown that the JAK inhibitor deuruxolitinib can promote hair regrowth in affected individuals.
- A Phase 3 trial tested deuruxolitinib in adults aged 18-65 with severe hair loss, finding that a significant percentage of patients experienced notable improvements in hair regrowth compared to a placebo.
- Although the treatment was generally well-tolerated with mostly mild side effects, further research is needed to assess long-term safety and the effects of stopping the treatment.
Article Synopsis
- Cendakimab is a treatment that targets and inhibits interleukin-13 (IL-13), which plays a role in the development of atopic dermatitis (AD), and is being studied for its effectiveness in treating this condition compared to a placebo.
- A phase 2 clinical trial involved 221 adult participants with moderate to severe AD who had not responded well to topical treatments, with patients receiving different doses of cendakimab or a placebo from May 2021 to November 2022.
- Results showed that the highest dose of cendakimab (720 mg, once weekly) significantly improved eczema symptoms compared to placebo, while other dosages did not achieve statistical significance, indicating potential for cend